1. The *Caliciviridae*: emerging pathogens with a high diversity
================================================================

The family *Caliciviridae* includes viruses that cause a broad spectrum of disease in a wide variety of mammalian, avian, and marine animals. This may range from acute gastroenteritis in humans (norovirus and sapovirus) to lethal encephalitis in immune deficient mice (murine norovirus), through haemorrhagic disease in rabbits and upper airway infection in cats (feline calicivirus). Although caliciviruses infect humans and non-humans, thus far there is no evidence for a zoonotic calicivirus reservoir.

1.1. Morphology and physicochemical properties
----------------------------------------------

The caliciviruses (CV) are small round viruses ranging from 27 to 32 nm in diameter. They are some of the smallest animal pathogenic viruses, and were originally referred to as the SRSV (small round structured viruses). Their surface displays a cup-like structure from which the name "calicivirus" was derived (*calyx*, cup; [Fig. 1](#fig1){ref-type="fig"} ) ([@bib34], [@bib65]).Fig. 1Morphology of the human pathogenic norovirus. Clinical stool samples were negatively stained with 2% phosphotungstate, pH 7.0, and examined by transmission electron microscopy. The typical cup-like surface of the virions is visible. Scale bar = 50 nm.

The cup-like surface of the virions is the capsid protein, consisting of 180 monomers known as virion protein 1 (VP1) which contains two domains: the shell (S), and the protruding (P) domain, being itself subdivided into P1 and P2 subdomains ([@bib31], [@bib65]). The P2 subdomain is located on the external part of the capsomeres, radiating out of the virion surface creating the cup-like shape. Structural comparison of the capsid proteins reveals genus-specificity within the P1 and P2 subdomains ([@bib32]). The P2 subdomain determines viral antigenicity and attachment of virions to cellular receptors ([@bib24]).

The viral capsid plays an important role in the resistance of virions to environmental changes. It resists high concentrations of chlorine, from 3.65 to 6.25 mg/L (residual concentration of 0.5--1.0 mg/L) ([@bib107]). This concentration significantly reduces the infectivity of other viral agents of gastroenteritis, i.e. poliovirus and rotavirus. Additionally, the viral capsid confers high resistance to physicochemical agents such as heat (60 °C for 30 min), acid (pH 2.7 for 3 h at room temperature), and organic solvents (20% ether at 4 °C for 18 h) ([@bib67]). These physicochemical properties contribute significantly to the highly contagious nature of these viruses.

1.2. Classification of the *Caliciviridae*
------------------------------------------

Classification of the *Caliciviridae* relies largely on phylogenetic analysis of the structural and non-structural viral genes, mainly due to the lack of cell culture systems to cultivate the viruses and thus to enable serological tests to be performed. The *Caliciviridae* comprises four accepted and two tentative genera, including human and non-human pathogenic viruses ([@bib45], [@bib65], [@bib66], [@bib138]). Non-human pathogenic viruses cluster exclusively in the accepted genera *Vesivirus, Lagovirus*, and the tentative genera *Beco/Nabovirus*, and *Recovirus*, whereas the genera norovirus and sapovirus include both human and non-human pathogens.

Phylogenetic analysis based on the complete VP1 sequence shows that noroviruses cluster tightly in five genogroups. The human pathogenic norovirus belongs to genogroups (G) I, II and IV. Genogroups I and II contain so far 8 and 17 genotypes, respectively ([@bib247]). The non-human pathogenic strains belong to norovirus GIII and V ([@bib157], [@bib160], [@bib159], [@bib163]). Genogroup II also contains the bovine and porcine noroviruses ([@bib137], [@bib233], [@bib234], [@bib247]). Genogroup IV, contains the feline (lion) and canine noroviruses ([@bib131], [@bib132]). Genogroup V contains the murine noroviruses (MNV) ([@bib239]). These MNV are readily propagated in RAW264.7 murine macrophage cells, as well as murine BV-2 cells and various murine cell lines ([@bib36], [@bib83], [@bib144], [@bib145], [@bib225], [@bib238]). Hence, MNV is an interesting surrogate for pathogenicity, multiplication cycle, and immunity studies that may also reflect properties of noroviruses. Infection in mice is usually asymptomatic. However, in immune deficient mice, i.e. (RAG2/STAT1^−/−^) MNV type 1 induces lethal encephalitis ([@bib87], [@bib105], [@bib145]). The human pathogenic norovirus (HuNV) is the major cause of human viral gastroenteritis ([@bib237]) and food-borne non-bacterial gastroenteritis ([@bib118], [@bib122]) worldwide. These viruses are highly contagious ([@bib224]) causing a self-limiting gastroenteritis with a higher prevalence during the winter time in all age groups. They are excreted for weeks after infection in asymptomatic patients ([@bib108], [@bib146], [@bib194]).

The genus *Sapovirus* contains five genogroups. The human pathogenic strains belong to sapovirus GI, II IV and V ([@bib44], [@bib54], [@bib81], [@bib153], [@bib190]), whereas the non-human pathogenic strains belong to GIII ([@bib45], [@bib66], [@bib74]). Human pathogenic sapoviruses are distributed globally. They cause viral gastroenteritis in all age groups ([@bib54], [@bib94], [@bib101], [@bib122], [@bib148], [@bib188]) including outbreaks in hospitals ([@bib101], [@bib196]), child day care centers ([@bib134]), and elderly persons homes ([@bib94]). The majority of human pathogenic sapovirus strains belong to GI and GII.

Viruses in the genus *Lagovirus* are causative agents of hemorrhagic disease and hepatitis in the European rabbit (*Oryctolagus cuniculus*), causing Rabbit haemorrhagic disease. An antigenically related but distinct virus infects the European hare causing brown hare syndrome ([@bib112]). A non-pathogenic strain designated rabbit calicivirus has been isolated ([@bib23]) and there is also compelling evidence of circulating non-pathogenic strains that either emerged originally as ancestral lineages of the recognized virulent extant viruses ([@bib143]) or still circulate in wild rabbits as widely divergent non-pathogenic viruses ([@bib50]). Other non-pathogenic strains arose as variants of virulent virus ([@bib49]).

The genus *Vesivirus* includes viruses that infect a broad variety of animals, including felines, reptiles, amphibians, fish and even nematodes ([@bib133], [@bib200], [@bib202]). The prototype of this genus is *vesicular exanthema of swine virus*, VESV, which displays sequence homology with San Miguel Sea Lion Virus (SMSV) ([@bib150], [@bib199]). Feline calicivirus (FCV), an important veterinary virus, infects domestic and wild cat species causing rhinitis and an ulcerative disease of the upper airways ([@bib178]). Systemic infections with FCV have also been described ([@bib35], [@bib48], [@bib95], [@bib167]).

The recently recognized tentative genera *Beco/Nabovirus* and *Recovirus* include viruses that infect bovines and non-human primates, respectively ([Fig. 2](#fig2){ref-type="fig"} ). Becovirus (*bovine enteric calicivirus*) and nabovirus (*Newbury agent-1* and NB, Nebraska) have been isolated from calf faeces ([@bib158], [@bib164], [@bib195], [@bib197]). Tulane virus was isolated from the faeces of rhesus macaques, being for the time being the only recognized virus in the genus *Recovirus* (*rhesus enteric calicivirus*) ([@bib43]).Fig. 2Classification of the *Caliciviridae*. Phylogenetic analysis of strains belonging to the so far defined genera (*Norovirus, Sapovirus, Lagovirus* and *Vesivirus*) and the two tentative genera *Beco/Nabovirus* and *Recovirus*, as indicated. The complete capsid sequence of the strains was aligned with Clustal X ([@bib59]) and a phylogenetic analysis performed with the neighbour-joining method using PAUP ([@bib217]). A bootstrap analysis with 1000 replicates was performed. The bootstrap values are indicated. The strains belonging to non-defined genogroups (GVI. VII, VIII and IX of sapovirus) are indicated by a question mark. The strains FCV/Dresden/2006/GE strain (*Vesivirus*, GenBank accession No. [DQ424892](ncbi-n:DQ424892)), and RHDV/Dresden/2006/GE (*Lagovirus*, GenBank accession no. [EF363035](ncbi-n:EF363035)) generated within the consortium VIZIER are highlighted in bold. The tentative Genera *Recovirus* and *Beco/Naboviru*s are indicated.

1.3. Genome organization of the *Caliciviridae*
-----------------------------------------------

*Caliciviridae* genomes consist of a single stranded positive-sense polyadenylated RNA molecule that averages 7500 nucleotides in length and containing either two or three open reading frames, depending on the particular genus ([Fig. 3](#fig3){ref-type="fig"} ). At the 5′-terminus of the genome, the so-called virion protein genome-linked (VPg) is linked to the viral RNA. The ORF1 encodes non-structural (NS) proteins present in all *Caliciviridae* in the following order: an N-terminal protein with unknown function (NS1-2), the NTPase (NS3), a small protein of about 20--30 kDa (NS4), the VPg (NS5), the viral protease (NS6), and the viral RNA-dependent RNA polymerase (RdRp, NS7). In the genera *Sapovirus, Lagovirus* and the tentative genera *Beco/Nabovirus*, the VP1 is encoded within the ORF1, whereas it is encoded in a separate ORF2 in the genera *Norovirus, Vesivirus*, and *Recovirus*. The 3-terminus of the genome, encodes a structural virion protein 2 (VP2), which is followed by an untranslated region, and a poly(A)-tail. Since they share some similarities with picornaviruses, the nomenclature of the non-structural proteins of the *Caliciviridae* was based on that of the picornaviruses, with the viral polymerase being called 3D-like, the 3C-like viral protease, the VPg, the 3A-like and the 2C-like protein. The increased knowledge on calicivirus replication and genome organization in the last years has led to a new nomenclature where the viral structural proteins are designated NS1/NS2 (N-terminal protein), NS3 (NTPase), NS4, NS5 (VPg), NS6 (protease), NS7 (RNA-dependent RNA polymerase, RdRp). The structural proteins are designated VP1 and VP2. In the sapovirus GI, IV and V, an additional ORF encoding a putative small basic protein has been described ([@bib34], [@bib82]).Fig. 3Comparison of the organization of the viral genome of the six calicivirus genera. The complete genome of the following strains is shown: Norovirus GII.4 (Hu/NLV/Dresden174/pUS-NorII/1997/GE strain, GenBank accession no. [AY741811](ncbi-n:AY741811)), vesivirus (feline calicivirus, FCV/Dresden/2006/GE strain, GenBank accession No. [DQ424892](ncbi-n:DQ424892)), sapovirus GI.1 (Hu/SV/pJG-SapI/DE strain, GenBank accession no. [AY694184](ncbi-n:AY694184)), and lagovirus (RHDV strain RHDV/Dresden/2006/GE, GenBank accession no. [EF363035](ncbi-n:EF363035)). The cleavage sites in the viral polyprotein precursor are indicated, as well as the putative molecular weight in kDa (K) of the resulting non-structural proteins.

1.4. Multiplication cycle of the *Caliciviridae*
------------------------------------------------

The multiplication cycles of the *Caliciviridae* remains poorly understood, mainly because of the limited possibilities of virus cultivation. Indeed, among the six calicivirus genera only the feline calicivirus and the murine norovirus can be easily propagated in cell systems, both being non-human pathogens. For the human pathogenic viruses, there are no suitable *in vitro* culture systems. Recently, a human norovirus was isolated and viral RNA was propagated for five sequential passages in small epithelial cells (INT-407) cultivated in suspension ([@bib215]). It remains unclear whether or not this system is suitable for isolation of the various norovirus genotypes.

Another approach to studying the molecular biology of calicivirus replication makes use of replicon systems, such as for the Norwalk-like virus ([@bib5], [@bib28]), and porcine enteric calicivirus ([@bib26], [@bib27]), but also reverse genetics systems for the murine norovirus ([@bib30], [@bib235]), the feline calicivirus ([@bib205], [@bib226]) and Tulane virus ([@bib43]). Those systems provide future opportunities for comparative analysis of the multiplication cycles of the different genera.

FCV has been used during the past two decades as a surrogate to investigate the replication strategy of the *Caliciviridae*. Many studies have brought insights into the replication of the vesivirus genome ([@bib204], [@bib208], [@bib205], [@bib209], [@bib210], [@bib211]). Lately, additional knowledge has been obtained from studies on the murine norovirus in RAW264.7 murine macrophages *in vitro* ([@bib206], [@bib238], [@bib239]).

Caliciviruses display in terms of genome structure and replication the following common characteristics:-Naked genomic length RNA is infectious *per se*, being a positive stranded RNA linked to the VPg at the 5′-terminus and bearing a poly(A)-tail at the 3′-terminus.-The ORF1 encodes a polyprotein that is further processed co-translationally by the viral protease, leading to at least 6 non-structural proteins involved in the replication of the viral genome.-The viral RdRp and the VPg play an essential role in the transcription and replication of the genomic, antigenomic RNA and subgenomic RNA.-The VPg acts as a cap-like structure and interacts with the initiation factors eIF4E and eIF3 ([@bib61], [@bib39]).-In the noroviruses, vesiviruses and possibly the recoviruses, the structural proteins (VP1 and VP2) are encoded by a subgenomic RNA.-In the sapoviruses, lagoviruses and possibly the beco/naboviruses, the VP1 is released from the ORF1-encoded polyprotein precursor after cleavage by the viral protease.-The VP2 is a small basic protein that is essential for virion generation ([@bib205]).

Schematically, the replication of caliciviruses is thought to contain eight steps ([Fig. 4](#fig4){ref-type="fig"} ). After attachment of the viral capsid to the cellular receptor, the virion is internalized. The RNA genome is then packaged in endocytic vesicles. The VPg linked to the genome interacts with the cellular translation machinery (the eukaryotic initiation factor 4 (eIF4) complex and the 40S ribosomal subunit ([@bib38], [@bib39]). Translation of the polyprotein and co-translational processing releases the non-structural proteins and their precursors, most importantly the protease-polymerase precursor (NS6-7^propol^), the protease (NS6^pro^), the RNA-dependent RNA polymerase (NS7^pol^), the putative NTPase (NS3^NTPase^), and the NS4-NS5^VPg^ proteins. These proteins are putatively involved in the enzymatic complex that replicates the genome, and synthesizes the antigenomic RNA.Fig. 4The multiplication cycle of the calicivirus. The replication of the calicivirus can be schematically subdivided into eleven steps. After attachment of the protein core to the cellular receptor, the virion is internalized in the cell (step 1). Uncoating of the viral genome (step 2) is followed by translation of the polyprotein precursor (step 3) and a co-translational processing releasing the non-structural proteins (step 4). Those proteins assemble in a replication complex (step 5) that synthesizes the antigenomic RNA (step 6), being itself used as a template for synthesis of the genomic RNA (step 7). The newly synthesized genomic RNA is translated as a polyprotein precursor (step 3) or being used for packaging in the assembled viral protein core (step 10). The antigenomic RNA is also the template for synthesis of subgenomic RNA (step 8). In noroviruses, vesiviruses and possibly recoviruses, the subgenomic RNA is translated as structural proteins, VP1 and VP2 (step 9). In sapoviruses, lagoviruses and possibly beco/naboviruses, the VP1 is released from the polyprotein precursor after processing by the viral protease. At a still not defined time in the multiplication cycle, assembly of the structural proteins as well as packaging of the genomic RNA occurs (step 10), followed by release of the mature virion from the cell (step 11).

This antigenomic RNA is the template for the subgenomic RNA, a peculiarity of the caliciviruses. In the noroviruses and vesiviruses, transcription of subgenomic RNA yields high amounts of structural proteins, the VP1 and VP2. In FCV, the VP1 is additionally cleaved by the viral protease releasing a leader protein (LC, *leader of the capsid protein*) and the capsid ([@bib135], [@bib210]). In the sapoviruses, lagoviruses and beco/naboviruses, the VP1 is released from the polyprotein precursor after processing by the viral protease. Experimental data on feline calicivirus describes a termination/reinitiation mechanism for VP2 translation ([@bib174]). This mechanism involves a so-called "termination upstream ribosomal binding site" (TURBS), that may regulate the ratio of VP1/VP2 production during replication ([@bib125]). A similar mechanism of termination-reinitiation has been recently reported in the murine norovirus ([@bib149]), resembling the termination-initiation mechanisms observed in other viruses, i.e. Influenza virus.

The antigenomic RNA is also the template for the genomic RNA, being subsequently translated in mature non-structural proteins. At a given time point in the multiplication cycle, packaging of the genomic RNA occurs, followed by release of the mature virion from the cell.

1.5. Calicivirus infection: epidemiology, transmission and clinical features
----------------------------------------------------------------------------

In the following section, we focus on the epidemiology and transmission of the human pathogenic caliciviruses (HuCV, norovirus and sapovirus), since these viruses are of prime interest for antiviral development.

### 1.5.1. Epidemiology of HuCV

The HuCVs are one of the most common causes of acute gastroenteritis worldwide, infecting both children and adults. In a recent report from CDC on outbreaks occurring in the USA from 1991 to 2002, norovirus infections were recognized as the most common cause of viral gastroenteritis in all ages in the US, accounting for about 33% of all outbreaks ([@bib126], [@bib236]). The majority of outbreaks were caused by strains belonging to GII.4 ([@bib109]) suggesting that this genogroup displays preferential features in terms of infectivity and/or transmission efficiency. Alternatively it could reflect increased virulence through enhanced activity of the viral enzymes, or shut-off of cellular host factors in the course of infection. Another important aspect relates to the dynamics of emergence in the noroviruses that correlates tightly with the propensity of disease dissemination through the community and over time, with new strains emerging through mutation and/or recombination. This is mainly supported by the emergence and circulation of norovirus and sapovirus recombinant strains ([@bib53], [@bib98], [@bib106], [@bib171], [@bib180], [@bib184], [@bib230]). A further aspect relates to zoonosis, since noroviruses and sapoviruses include strains that are human or non-human pathogenic. A high prevalence of antibodies binding norovirus and sapovirus and neutralizing Tulane virus have been recently detected in captive juvenile macaques ([@bib42]). Additionally, sera collected from norovirus outbreak patients displayed a neutralizing effect on Tulane virus infectivity in vitro ([@bib42]). This data, although preliminary, may indicate a possible cross-species transmission of human and/or non-human pathogenic calicivirus, although a cross-reactivity of the sera is not to be excluded. Moreover, cross-species transmission of the bovine norovirus Newbury2/76/UK strain has been recently invalidated by the fact that the carbohydrate ligand required for attachment of the virus is absent from human tissues ([@bib243]). All in all, the experimental and epidemiological data generated so far are not strongly in favor of a cross-species transmission.

### 1.5.2. Transmission and host resistance

Transmission of HuCV occurs via the fecal-oral route, but virus can be transmitted via aerosols, as observed during explosive vomiting ([@bib109], [@bib110], [@bib111]). The environmental resistance of HuCV combined with their high infectivity (with an infectious dose of 10--100 viral particles), facilitates their efficient transmission. Human susceptibility to infection by noroviruses is also dependent on the blood group of the individual (A, B, O). The histo-blood group antigens (HBGA) are one of the recognized binding receptors for noroviruses ([@bib84], [@bib96], [@bib117], [@bib130], [@bib182]). HBGA are present on the surface of erythrocytes and mucosal epithelial cells or as free oligosaccharides in milk, saliva and gut fluid ([@bib129]). A recent study underlies the difference of HBGA present in saliva and milk. In human milk, the HBGA are synthesized in higher quantities and display smaller molecular weights and different backbones, although HBGAs of high molecular weight may also be found ([@bib89]). This variability in HBGA content and nature seem to play an important role in modulating the specific binding of human pathogenic norovirus to the HBGA present in saliva and/or milk, and subsequent transmission.

Binding of the VP1 protein to the HBGA has been shown to occur in the P2 subdomain ([@bib22], [@bib220], [@bib221]). The differential binding of the P2 subdomain to the HBGA induces a differential susceptibility of humans to infection with the different norovirus genogroups. Binding of the P2 subdomain is modulated by the phenotype of the fucosyl-transferase (FUT) enzyme. The fucosyl-transferase (FUT) conjugates a fucosyl residue to the N-acetyl-glucosamine of the HBGA. Individuals lacking a functional FUT2 enzyme are called non-secretors, as they do not secrete the ABO HBGA in their saliva and the gut fluid. Individuals harboring a functional FUT2 enzyme are called secretors, displaying the A, B or Lewis^b^ phenotypes. This is related to the expression of the enzymes A and B type 1 that conjugate the precursor H type 1 (HBGA) with a glucosyl residue, or through the FUTa1-4 enzyme with a fucosyl residue. Non-secretors (Lewis^a^) are resistant to infection with the majority of norovirus stains. The non-secretor phenotype is present in about 20% of the European and North American population ([@bib129]).

It should however be kept in mind that neither sapovirus genogroup I nor sapovirus GV virus-like particles display such a binding to the ABO HBGA ([@bib193]), indicating a different cellular receptor and possibly mechanism of internalization for noroviruses and sapoviruses.

2. Development of antivirals against caliciviruses
==================================================

Based on our knowledge of the calicivirus genome organization, molecular biology, transmission and replication, potential antiviral strategies are now at least conceivable. In the following section, we will describe potential calicivirus targets for drug development. Possible antiviral approaches using the experimental data on the structure and function of the viral enzymes of replication that was generated through a successful collaboration within the European consortium VIZIER are also presented.

2.1. Targeting the attachment and internalization of the virions
----------------------------------------------------------------

In the first steps of viral infection, attachment of the virions to the cell surface and interaction with a specific receptor leads to its internalization, followed by uncoating of the viral genome and release into the cytoplasm. To inhibit viral infection of the cell, it may therefore be possible to inhibit binding of the virion and/or internalization and/or release of the viral genome.

Recent work on the feline calicivirus identified the specific receptor for internalization of the virion ([@bib128]). FCV attaches to a-2-6-linked sialic acids, but uses the junctional adhesion molecule 1 (JAM-1), a member of the immunoglobulin superfamily, for internalization in Crandell-Rees feline kidney (CRFK) cells. JAM-1 is expressed in tight junctions in a variety of cells. An anti JAM-1 antibody reduced FCV binding to CRFK cells and thus reduced infectious virus yields ([@bib128]). This advance in the characterization of the specific receptor may represent an interesting antiviral approach by targeting the calicivirus receptor (i.e. JAM-1) using appropriate monoclonal antibodies. However, considering the broad diversity of host cells (enteric cell, respiratory epithelium, dendritic cells, or neuronal cells), important hurdles remain. For instance, the murine norovirus has been recently reported to bind a ganglioside GD1a present on the surface of murine macrophages ([@bib223]). This ganglioside is thought to mediate attachment, but internalization probably requires additional factors, for example, an integrin. A recent study has reported on the involvement of a cholesterol dependent pathway for entry of murine norovirus in RAW264.7 cells, with the clathrin and caveolae pathways being not required for cell entry ([@bib57]). Whether or not this phenotype is common to other noroviruses is unclear. It is also unknown whether GD1a is involved alone in binding of the virion or other membrane proteins interact with it. In this case, inhibition of binding to one receptor may lead to inhibition of viral entry in the cell, through a mechanism of steric or allosteric blockade of the interaction between virus and receptor.

There is still little known about the internalization receptor of lagoviruses and sapoviruses. The attachment of HuCV to ABO HBGA, heparan sulfate, and sialyl-Lewis x ([@bib187], [@bib219]) has been demonstrated *in vitro* using virus-like particles (VLPs). The lack of a cell culture system to reproduce the human pathogenic calicivirus, is impeding further work in this subject area.

An interesting antiviral approach may be to block the interaction of the P2-subdomain of norovirus with the HBGA. In a recent study ([@bib46]), Feng et al. screened a compound library using a saliva-based receptor binding assay for blocking the interaction of secreted HBGA and VLPs of the norovirus strain VA387. VLPs display similar antigenic properties to native virions and have been used as tools to investigate virus--host interactions and immune responses in animal models, and for screening potential anti-norovirus candidates ([@bib69], [@bib90], [@bib91], [@bib99]). In 14 of the 5000 compounds screened, an EC~50~ value of less than 15 μM was found, and in 2 compounds, an EC~50~  \< 5 μM. Because HuCV are thought to replicate in intestinal cells, inhibition of attachment of HuCV to the HBGA receptor may represent an interesting strategy to inhibit infection of the cell. If applied early in the course of infection, it may also block propagation of the virions within the tissue. This kind of treatment may be suitable in a preventive set-up in the course of spatial limited outbreaks occurring for example on cruise ships.

A similar approach relies on trapping the norovirus in glycosylated hydrogels ([@bib246]). The trapping capacity of hydrogel was estimated to be about 24 μg VLPs per mg. Although promising, this approach is more suitable to prevent transmission of norovirus from person-to-person.

Because, in contrast to noroviruses, the human pathogenic sapoviruses do not rely on attachment to HBGA, additional data concerning virus binding and entry will be needed to bring the proof-of-principle for an attachment-inhibition-based antiviral approach in caliciviruses.

2.2. Targeting uncoating and release of the viral genome
--------------------------------------------------------

Many viruses enter the cell and the cytoplasm through endocytic vesicles ([@bib168], [@bib198]). In mammalian cells, various endocytosis pathways have been described: macropinocytosis, phagocytosis, endocytosis via caveolae/lipid rafts, and clathrin-mediated endocytosis. Following endocytosis, uncoating of the viral genome may depend on lowering of the pH in the endocytic vesicles. The pH change leads to conformational change of the viral capsid, with exposition of motives located on the subdomains ([@bib14]). In an experimental set-up, the low pH-environment of the endosome induced structural changes of the FCV capsid leading to release of the viral genomic RNA ([@bib216]). Hence, a possible antiviral approach may be to use compounds or short peptides that inhibit rearrangements of the viral surface related to pH change. Another approach may rely on inducing pH-modifications in the different compartments of the cell, and subsequently the intra-cellular pH-gradient. Two different compounds are known to inhibit the reduction of the endosomal pH: a weak basic compound (chloroquine), and a macrolide antibiotic that selectively inhibits the vacuolar type of vesicular proton ATPase (Bafilomycin A1). Bafilomycin A1 and chloroquine increase in a concentration-dependent manner the pH of the endosomal compartment and may be used to inhibit uncoating of the viral genome by inhibiting acidification of the endosome. Interestingly, chloroquine and Bafilomycin A1 inhibit FCV infectivity *in vitro* ([@bib216]). Moreover, Chlorpromazine, a compound known to inhibit clathrin-mediated endocytosis, inhibits internalization of FCV *in vitro* ([@bib216]). It remains unclear whether or not other caliciviruses display similar entry and uncoating mechanisms. Recent data on murine norovirus revealed that infection of murine RAW264.7 was not inhibited by reagents that raise endosomal pH ([@bib57]). Nevertheless, and because all three substances are commercially available, they represent a promising approach to control infection by FCV.

2.3. Targeting the viral genomic RNA
------------------------------------

After its release into the cytoplasm, the viral mRNA is recruited to the endoplasmic reticulum for translation to produce the viral polyprotein. At this stage, inhibition of the function of the whole genomic RNA and/or parts of it stops viral replication. To this end, two strategies have been developed in *Caliciviridae*, both making use of nucleic acids targeting the 5′-end and/or the 3′-end of the genome. Comparative analysis of the structural features of members of the *Caliciviridae* has shown that all strains display stem-loops and hairpin structures at the 5′-terminus and the 3-′-terminus of the viral genome, respectively ([@bib195]).

Using an experimental approach based on the murine norovirus reverse genetic system, disruption of the 5′-stem loops or the 3′-hairpins strongly impaired viral replication in RAW264.7 murine macrophages *in vitro* ([@bib195]). Moreover, a polypyrimidine tract located at the 3′-terminus of the genome has been incriminated in regulating viral fitness and virulence in a small animal model of infection ([@bib7]). This indicates that those structures play an important role in the infectivity of the MNV.

Both regions are preferentially targeted by nucleic acid based approaches as both bear highly conserved sequences within genera (i.e. in FCV, [Table 1](#tbl1){ref-type="table"} ). The nucleic acid-based strategies are the antisense approach and the post-transcriptional gene silencing (or RNA-interference) approach. There are important prerequisites for the successful implementation of a nucleic acid-based antiviral approach. First, the target sequence has to be involved in viral replication. Additionally, it must be accessible for oligonucleotide hybridization, and most importantly when dealing with RNA viruses with high genomic variability it must be conserved among different viral species. Hence, the regions that are preferentially targeted reside within the 5′- and 3′-UTRs of the viral genome, where conserved regions may span entire genera.Table 1Sequences of the 5′-UTR and 3′-UTR of feline calicivirus strains displaying 100% identity to the FCV/Dresden/2006/GE strain (GenBank accession no. [DQ424892](ncbi-n:DQ424892)) used for the antiviral nucleic acid based approach. The nucleotide positions as well as the GenBank accession no. of the strains are indicated.GenBank accession no. of the FCV strains[M86379](ncbi-n:M86379)[AY560113](ncbi-n:AY560113)[AY560114](ncbi-n:AY560114)[AY560115](ncbi-n:AY560115)[AY560116](ncbi-n:AY560116)[AY560117](ncbi-n:AY560117)[AY560118](ncbi-n:AY560118)[L40021](ncbi-n:L40021)NC0014815-UTR (nt position)1--631--571--571--631--501--571--561--631--633--UTR (nt position)7536--75707533--75617536--75707542--75737542--75737536--76067545--75947542--75857542--7585

### 2.3.1. The antisense approach

The antisense approach uses DNA-oligonucleotides targeting conserved regions of the viral genome. It has been applied in various models of viral infections with positive-stranded and negative-stranded RNA viruses ([@bib52], [@bib124], [@bib162], [@bib212], [@bib213], [@bib214]).

In the *Caliciviridae*, peptide-linked phosphorodiamidiate morpholino oligomers (PPMOs) targeting a sequence near the 5′-UTR of the murine norovirus genome were effective in reducing translation of viral proteins *in vitro* ([@bib19]). Our preliminary investigations have made use of the PPMO-approach to inhibit multiplication of the feline calicivirus *in vitro*. Seven PPMOs (kindly provided by Dr. David Stein, AVI Biopharma) were designed to target the viral genome in particular the 5′-UTR or the 3′-UTR of the feline calicivirus genome ([Table 2](#tbl2){ref-type="table"} ). In a cell proliferation assay, the lowest EC~50~ observed was of 20.4 μM, with a selectivity index of 9.8 ([Table 3](#tbl3){ref-type="table"} ).Table 2Sequence characteristics of the oligonucleotides used for antiviral nucleic acid based approach.OligonucleotideSequence (5′--3′ orientation)Length (nt)Target (nt position)PPMO-1GAC ATT GTC TCA AAT TTC TTT TAC241--24PPMO-2GCA CAT GCT CAA ACT TCG AAC AC235294--5313PPMO-3CCC ATG TAG GAG GCA GTA AGA GG237237--7259PPMO-4CCC TCI TGI GIT TAG GCG CTA GAG CGG241497--1520PPMO-5^a^GTA AAA GAA ATT TGA GAC AAT GTC241--24PPMO-6CCG CTC TAG CGC CTA ACC CCA GIG247658--7680PPMO-7TGC TCT GTC TAC AGT AGT GTC A226159--6180  siR19ACU CUG AGC UUC GUG CUU ATT2129--47UAA GCA CGA AGC UCA GAG UTT21  siR20CCU GCG CUA ACG UGCUUA ATT215321--5339UUA AGC ACG UUA GCG CAG GTT21Table 3Antiviral activity and cell toxicity of the oligonucleotides used in the nucleic acid based approach. The EC~50~ and CC~50~ values are measured in a colorimetric cell-proliferation assay, as described by others ([@bib161]).OligonucleotideEC~50~ (μM)CC~50~ (μM)SI (CC~50~/EC~50~)PPMO-120.4\>2009.8siR190.44\>2.55.7

Phosphorodiamidiate morpholino oligomers (PMO) targeting the 5′-UTR of the FCV genome were used in 3 clinical trials relating to FCV outbreaks. From day 1 of infection, PMOs were administered parenterally to 112 kittens for 7 days in different dosages (0.7--5.0 mg/kg). The PMO displayed a dose-dependent effect. Of the 59 animals treated, 47 survived the infection. In comparison, in 31 animals not treated with PMO, only 3 survived the infection ([@bib201]).

Although preliminary, these experimental data indicate that PPMOs may represent an interesting approach for treatment of calicivirus infections.

### 2.3.2. Post-transcriptional silencing using RNA-interference

Another approach targeting the viral genome is post-transcriptional silencing using sequence specific RNA-Interference. The use of RNA interference to silence exogenous RNA such as viral genomic RNA has been extensively reported ([@bib77]). Different approaches using siRNA have been employed in viral infection models *in vivo* and *in vitro* ([@bib16], [@bib18], [@bib231], [@bib56], [@bib55], [@bib227], [@bib245], [@bib17]).

Major problems with the RNAi-approach reside in the design of the siRNA, and the delivery of the molecules to the targeted cell, and furthermore to the cellular compartment where the targeted RNA is located. Another problem relates to the stability of the siRNA as well as to its bioavailability ([@bib113]). A further problem relates to the off-target effects observed when the seed sequences of the siRNA cross-react with host cellular mRNA ([@bib97], [@bib115]). Nevertheless, one major advantage of the RNAi-based strategy is the faster and more efficient development of lead compounds compared to classical small molecules. This is particularly of interest for RNA viruses with high genomic variability, such as the *Caliciviridae*, and more particularly the human pathogenic norovirus. Indeed, in the case of emergence and pandemics of new norovirus variants, the rapid optimization of siRNA molecules may facilitate accelerated design and synthesis of RNAi-compounds and thus, control of the infection. Moreover, through judicious design of the RNAi-molecules, as well as the correct choice of the targeted sequence, broad-spectrum activity of the antiviral can be achieved. In *Caliciviridae*, a conserved sequence is of interest, for example, specific regions within the 5′-UTR in FCV. However, this region may be problematic because of binding of cellular translation products to the potential antiviral molecules, possibly causing steric blocking of the siRNA.

As observed for small molecules, the administration of siRNA may also induce the emergence of resistant mutants. Therefore, another strategy would be to target cellular factors that are indispensable for viral replication, but dispensable for cellular metabolism.

In a preliminary set-up, we have used small interfering RNA molecules that target the 5′-UTR and the subgenomic region of the FCV genome (FCV/Dresden/2006/GE strain, GenBank accession No. [DQ424892](ncbi-n:DQ424892)). In a prophylaxis model of infection, CRFK cells were transfected with siRNA, followed by infection of the cells. The siRNA completely inhibited viral multiplication ([Fig. 5](#fig5){ref-type="fig"} ). In a cell proliferation assay, the EC~50~ was of 440 nM that is about 50-fold lower than the EC~50~ observed with PPMOs targeting the same sequence ([Table 3](#tbl3){ref-type="table"}). Although provisional, this data suggests that post-transcriptional gene silencing may be a potential antiviral approach through targeting of the viral genome.Fig. 5Inhibition of calicivirus particle formation in CRFK-monolayer after infection with the FCV/Dresden/2006/GE strain (GenBank accession No. [DQ424892](ncbi-n:DQ424892)). Two siRNA (siR19 and siR20) targeting conserved sequences in the 5′-UTR and 3′-UTR, respectively, were used. The siRNA (330 nM) was transfected into the CRFK cells 5 h prior to infection with FCV. Plaque assays were performed as described by others ([@bib64]), yielding a viral titre of 500 PFU/ml. The siRNA completely inhibited viral multiplication in the CRFK cells.

In summary, in comparison to small molecules, the nucleic-acid based approach offers many advantages that may render it attractive as an antiviral strategy. Its strengths rely on its selectivity, and on the possibility of rapid optimization of lead compounds, in particular in the case of emerging viruses with high genomic variability. Nevertheless, several pre-requisites have to be fulfilled before its implementation as a therapeutic tool. Clearly, two major hurdles would be its bioavailability and its specific delivery to the infected cells.

2.4. Targeting the translation of the viral genome
--------------------------------------------------

Translation of the viral genome is the first step in the replicative cycle of the positive-sense RNA viruses. Initiation of translation has been reported to be dependent on the interaction of the VPg with cellular translation factors, such as the eIF4F initiation complex.

This complex is a key player in the initiation of translation of eukaryotic mRNA. It assembles the pre-initiation complex to the mRNA via its interaction with the cap-structure and the eIF3 ([@bib60], [@bib103]). The eIF4F complex consists of an RNA helicase (eIF4A), a factor directly interacting with the cap-structure of the mRNA (eIF4E), and a binding protein (eIF4G) to other cellular translation modulators such as the poly(A)-binding protein (PABP) and eIF3.

In FCV and MNV, the VPg interacts with the initiation factors eIF4E and eIF3, whereas the VPg of NV interacts with the eIF4E ([@bib61]). In both FCV and MNV, translation of the polyprotein precursor depends on the presence of a functional component of the eIF4F complex, the RNA helicase. Indeed, treatment of FCV infected cells with a small molecule inhibitor of eIF4A (hippuristanol) blocks translation of viral proteins. Hippuristanol interacts with the C-terminus of eIF4A with subsequent inhibition of its NTPase hence helicase activity ([@bib20]). Importantly, hippuristanol is expected to have toxic effects on the cells due to the inhibition of host cell -- as well as calicivirus -- protein synthesis.

In a similar way, pateamine stimulates both helicase and NTPase activities of eIF4A, dysregulating its function within the translation complex ([@bib20]). In this sense, using inhibitors of components of the eIF4F complex, i.e. hippuristanol ([@bib20]), or dysregulators of the eIF4A function, i.e. pateamine ([@bib123]) is a promising approach.

Another important regulator of translation is the interaction of the 5′- and 3′-untranslated regions of the viral genome with cellular host factors involved in protein translation. At both ends of the calicivirus genome, untranslated regions (UTR) of variable size between genogroups and genera are present. Although experimental evidence for the direct interaction of these structures with the translation machinery is still lacking, disruption of the structures in a model of infection *in vitro* led to strong impairment of the replication of murine norovirus. These data support the concept of an important role for the structured termini of the calicivirus genome in the viral multiplication cycle. These properties of the calicivirus genome being highly structured are very common amongst many other positive-strand RNA viruses ([@bib62], [@bib78]) such as picornaviruses (i.e. the CRE-element ([@bib63]), or the IRES ([@bib169], [@bib241])) or flaviviruses ([@bib229], [@bib232], [@bib70], [@bib71], [@bib72], [@bib175], [@bib176], [@bib177]).

The 5′- and 3′-UTR of the viral genomes are highly structured sequences that fold in a functional conformation. In order to ensure appropriate folding and subsequent interaction with viral structural and non-structural proteins, cellular chaperones such as the polypyrimidine tract-binding protein (PTB) are required ([@bib85], [@bib228]). The PTB is expressed in the nucleus and cytoplasm acting as a regulator of splicing pathways ([@bib58], [@bib114]). The PTB was postulated to work as a chaperone for the viral genomic RNA, implicated in folding to secondary structures located at the 5′-terminus of the genome. In FCV, the PTB interacts specifically with sequences located at the 5′-UTR of the genome ([@bib104]), and is required for multiplication of the FCV in host cells. In murine norovirus, the PTB binds to a polypyrimidine tract located within the 3′-UTR of the viral genome ([@bib7]). This interaction was reported not be essential for virus replication, although being an important regulator of viral fitness and virulence ([@bib7]).

Host cell factors such as Unr ([@bib21]), poly(rC)-binding protein (PCBP) ([@bib166]), La autoantigen ([@bib140]), hnRNP A1 ([@bib92]) and poly(A)-binding protein (PABP) interact with the viral genome of a variety of RNA viruses. The host cellular factors modulate translation and processing of the viral polyproteins, but also the translation of host cell mRNA. In human pathogenic Norwalk virus, PTB ([@bib76]), La autoantigen, hnRNP and PCB-2 interact with both the 5′-UTR and the 3′-UTR (for La and PTB) ([@bib76]), although no functional roles of those proteins in norovirus replication have been described so far.

Taken together, this knowledge on translation initiation in the *Caliciviridae* offers interesting possibilities (i.e. peptides, nucleic acids) to target the interaction of the viral genome and/or the VPg with cellular host factors of translation, with subsequent inhibition of viral protein synthesis.

2.5. Targeting replicative viral enzymes
----------------------------------------

### 2.5.1. The viral chymotrypsin-like protease

The calicivirus chymotrypsin-like protease plays a central role in viral replication. The molecular mechanisms underlying the catalytic activity and specificity of the norovirus, sapovirus, murine norovirus and feline calicivirus protease have been extensively investigated. Knowledge on the regulation of calicivirus polyprotein processing is an important prerequisite for the development of antiviral drugs to control calicivirus infection.

The viral protease is involved in early steps of replication. Its active form is the viral protein NS6^pro^, or a protein precursor consisting of the viral protease and polymerase NS6^pro^NS7^pol^. The cleavage pattern of the calicivirus polyprotein precursor by the viral protease has been investigated both in cell-free expression systems ([@bib12], [@bib120], [@bib192]) and in mammalian cells ([@bib28], [@bib191], [@bib192], [@bib206]). Processing of human Norwalk virus in Huh-7 cells ([@bib28]) and of a murine norovirus strain in the macrophage-like cell line RAW264.7 ([@bib206]) have shown that both the NS6^pro^NS7^pol^ precursor and the NS6^pro^ are present in infected cells. A similar observation was reported for a related non-human pathogenic calicivirus strain, the rabbit hemorrhagic disease virus (RHDV, genus *Lagovirus*). However, in another human pathogenic calicivirus, the sapovirus (SV), NS6^pro^NS7^pol^ is the only protein detected in a cell-free system ([@bib155], [@bib156]). In the case of the pathogenic feline calicivirus (FCV), the NS6^pro^NS7^pol^ precursor is detected in mammalian cells ([@bib207], [@bib210], [@bib211]). In accordance with our observations ([@bib189]), evidence for autocatalytic cleavage of norovirus NS6^pro^ from the polyprotein precursor has been presented ([@bib12], [@bib28], [@bib120], [@bib191], [@bib206]).

The cleavage specificity and efficiency of norovirus and sapovirus NS6^pro^ and NS6^pro^NS7^pol^ were examined *in vitro* using peptides bearing the cleavage sites of the polyprotein. In norovirus, Gln-Gly is required between the P1 and P1′ positions framing the scissile bond of the peptide to be cleaved by the protease. In sapovirus, cleavage specificity and efficiency seem to be modulated by the positions P4, P1 and P2′ of the scissile bond.

The cleavage specificity observed is explained by studies on the structure of the norovirus protease ([@bib147], [@bib244]) and sapovirus protease ([@bib181]). In the sapovirus NS6^pro^, the catalytic triad consists of Cys~116~-His~31~-Glu~52~. His~131~ is located at the bottom of the S1 pocket. Its role is to interact with the P1 side chain of the substrate, as observed in norovirus NS6^pro^ (see below). Another His residue, His~102~ plays an important role by holding Glu~52~ in its proper position in the triad. This feature does not exist in norovirus 3C-like protease.

The crystal structure of norovirus NS6^pro^ has revealed that five residues govern the specificity of substrate binding to the protease: His~157~ and Ala~160~ in the S1 pocket, and Ile~109~, Arg~112~, and Val~114~ in the S2 pocket ([@bib147]). In the S1 pocket, the His~157~ residue interacts with the Gln (P1) residue at the scissile bond ([@bib244]). His~157~ is important for substrate binding since its mutation severely reduces the activity of NS6^pro^ ([@bib203]). In other RNA viruses (human rhinovirus, hepatitis A virus, poliovirus, and coronavirus), similar observations were made, with the His at the S1 site interacting through its imidazole ring with the carboxamide chains of the P1 residue ([@bib1], [@bib2], [@bib3], [@bib13], [@bib136], [@bib142], [@bib242]). Furthermore, the presence of a small residue (Gly or Ala) at the P1′ positions of the scissile bonds in norovirus polyprotein is consistent with the limited volume allowed for the P1′ residue in the S1 pocket of norovirus protease ([@bib147]). In contrast, the S2 hydrophobic pocket of the norovirus protease is large enough to accommodate the side chain of a bulky hydrophobic amino acid such as Phe, Met, or Leu ([@bib147]). Similarly, the binding sites for the P3 and P4 residues in norovirus NS6^pro^ are reported to be large enough to accommodate residues of various sizes (i.e., Ser, Gly, His, or Thr in the P3 pocket, and Phe, Met, Ala, or Leu in the P4 pocket) ([@bib147]).

Because of the specificity of cleavage of the scissile bonds of the polyprotein of the various calicivirus genera, peptidomimetics or substrate-like peptides may constitute an interesting strategy for the inhibition of viral replication. Another possible approach may be to use inhibitors that block the protease active site. For the implementation of such an approach at least two important barriers have to be crossed. These are (i) the large size of the peptidic compounds, and their possible poor bioavailability and (ii) the limited in vivo stability of peptides. Nevertheless, because of the extensive knowledge generated on the structure and function of the chymotrypsin-like protease, targeting the viral protease may be one of the most promising approaches to inhibit calicivirus replication.

### 2.5.2. The RNA-dependent RNA polymerase

The RdRp is involved in synthesis of the genomic, subgenomic and antigenomic RNA of the calicivirus. Structural analysis of the norovirus, sapovirus and RHDV RdRp has revealed a right-hand structure typical for template-dependent polymerases ([@bib15], [@bib33], [@bib47], [@bib151], [@bib152]). Interestingly, structural similarities that exist in the shortened loop section of RHDV, sapovirus and norovirus NS7^pol^ ([@bib151]) suggest similar mechanisms for activation of RNA elongation in *Caliciviridae*. Nevertheless, sapovirus NS7^pol^ displays functional similarities to norovirus NS7^pol^, but not to vesivirus (FCV) and lagovirus (RHDV) RdRp. This relates mainly to the ability of both sapovirus and norovirus NS7^pol^ to initiate RNA synthesis *de novo* on heteropolymeric templates, with a primer-dependent initiation of RNA synthesis on homopolymeric templates, and a terminal transferase activity with a preference for CTP ([@bib185], [@bib51]).

The potential strategies to inhibit the calicivirus RdRp fall in two categories: nucleoside analogue inhibitors and non-nucleoside inhibitors.

Nucleoside analogs all display similar mechanisms of inhibition of the RdRp activity. The nucleosides penetrate the cell and undergo phosphorylation by triphosphate, giving nucleotides. They are then incorporated in the polymerized nucleic acid chain elongated by the RdRp, leading to chain termination. In a preliminary investigation and in order to validate both polymerases of the HuCV as targets for antiviral design, we have tested five different nucleoside analogs for their potential as inhibitors of the activity of the HuCV polymerases. As shown in [Fig. 6](#fig6){ref-type="fig"} , both the 2′-arauridine-5′-triphosphate (TriLink technologies) and the 3′-deoxyuridine-5′-triphosphate (TriLink technologies) displayed potent inhibitor activities against the HuCV polymerases at a concentration of 50 μM. In contrast, other nucleoside analogs did not show any activity against the HuCV polymerase. This provisional data is in favor of using the HuCV RNA-dependent RNA polymerase as a target for the development of antiviral drugs ([Fig. 6](#fig6){ref-type="fig"}).Fig. 6Inhibition of the activity of norovirus and sapovirus RNA-dependent RNA polymerases by nucleoside analogues. (A) Assessment of the activity of the norovirus RNA-dependent RNA polymerase was determined as previously described ([@bib183], [@bib185]). (B) Assessment of the activity of the sapovirus RNA-dependent RNA polymerase NS7^pol^ was determined as previously described ([@bib51]). 2′-Fluor-UTP, 2′-fluorouridine-5′-triphosphate. 2′-O-Methyl-UTP, 2′-O-methyluridine-5′-triphosphate. 2′Ara-UTP, 2′-arauridine-5′-triphosphate; 3′-deoxy-UTP; 3′-deoxyuridine-5′-triphosphate. 2′-O-Methyl-GTP, 2′-O,methylguanidine-5′-triphosphate. The mean and the standard error of the mean of three independent experiments are shown. CPM, counts per minute. Each of the compounds was incubated at a concentration of 50 μM.

Another substance of interest is ribavirin. Ribavirin (1-α-[d]{.smallcaps}-ribofuranosyl-1,2,4-triazole-3-carboxamide) efficiently inhibits norovirus replication *in vitro* ([@bib25]). Ribavirin is a synthetic guanosine analogue, has a broad range of antiviral activity against RNA but also DNA viruses. In the NV replicon system, Ribavirin was reported to display an EC~50~ of 40 μM ([@bib25]). This value was 100 μM when MNV-infected RAW264.7 cells were treated ([@bib25]). In feline calicivirus, Ribavirin was however not effective *in vivo* ([@bib172], [@bib173]). Although the experimental data *in vitro* is encouraging, and because Ribavirin has a lot of adverse effects and a very narrow therapeutic index, it is at this time point not suitable for the treatment of a disease such as viral gastroenteritis with almost no lethal outcome.

### 2.5.3. The VPg

The VPg is putatively linked to the genomic RNA in caliciviruses, although experimental evidence of this linkage is still lacking for non-human pathogenic caliciviruses. The VPg is involved through uridylylation in a protein-primed dependent initiation of RNA synthesis of antigenomic and presumably genomic RNA. Uridylylation is thought to occur at tyrosine 24 in the protein, as shown through mutation analysis in the FCV reverse genetics system ([@bib141]). Uridylylation has been experimentally proven for noroviruses ([@bib11], [@bib185]), and for lagoviruses ([@bib127]).

Uridylylation is thought to involve the viral RdRp, the VPg, as well as the polyadenylated viral genome. Whether or not the antigenomic viral RNA is involved remains unknown, but by analogy with poliovirus it could potentially be.

Prevention of uridylylation of the viral genome could also be an interesting antiviral approach, through inhibition of the interaction of the VPg with the RdRp, and/or with the viral genome, resulting in the shut-off of synthesis of the viral genomic RNA.

### 2.5.4. The NTPase

Another possible target for antiviral therapy is the calicivirus NTPase. The NTPase (NS3) displays the canonical motives of viral NTPases as described for picornaviruses and flaviviruses, for instance. The occurrence of the three motives A (GXXGXGKS/T), B (DD/E) and C (KXXXFXSXXXXXS/TTN) classifies the calicivirus NS3^NTPase^ in the superfamily 3 of RNA helicases ([@bib170]), although experimental evidence *in vitro* and in cell culture for its putative RNA unwinding activity is still lacking. The recombinant NS3^NTPase^ displays NTPase activity in *vitro*, but does not bind RNA, nor does it unwind RNA--RNA or RNA--DNA-duplexes ([@bib170]). Here, future experimental evidence may help in designing innovative antiviral strategies targeting this important enzyme of calicivirus replication.

By analogy with the flavivirus NTPase/helicase that has been extensively studied and characterized functionally and structurally, inhibitors of the NTPase/helicase may act by (i) competitive inhibition and blockade of the NTP binding site, or (ii) by conformational changes through immobilization of the switch region, (iii) by competitive inhibition of RNA binding, or (iv) by inhibition of unwinding via steric blockade of translocation of the NTPase/helicase along the template RNA.

2.6. Targeting assembly of the replication complex
--------------------------------------------------

The viral enzymes of replication interact in a complex of multiple components, constituting the replication complex. This complex may be transient, or relatively stable; and the ability of the viral enzyme to interact with any one partner of interest may be significantly influenced by other complex members. In caliciviruses, the replication complex is predicted to involve mainly three viral enzymes: the RNA-dependent RNA polymerase, the viral protease, and the NTPase/helicase. In addition to the viral genomic/antigenomic and/or subgenomic/anti-subgenomic RNA, structural viral proteins may be included, but also the VPg, or the N-terminal protein. Experimental data using noroviruses has shown that the N-terminal protein interacts in a vesicular complex with the VAP-A-Protein (*vesicle-associated membrane protein-associated protein A*) leading to inhibition of intracellular protein trafficking ([@bib41]). In FCV, the interaction of NS2 with NS3^NTPase^, NS4, NS5^VPg^ and NS6-7^propol^ has been demonstrated *in vitro* ([@bib102]). The FCV NS6-7^propol^ was also reported to interact with the NS5^VPg^, interacting itself with the structural protein VP1 ([@bib102]).

So far, the determinants of assembly and structure of the replication complex, as well at its role in regulating the life cycle of the virus remain poorly understood. Moreover, our recent results generated within the VIZIER-Consortium indicate that small molecules inhibiting viral replication in mammalian cells might possibly target the replication complex, specifically the interaction of the viral enzymes within the complex. The effect of small molecules would mainly be to destabilize the complex, subsequently inhibiting the replication of the viral genome, hence the multiplication of the virus within the cells. Therefore, knowledge of the functional and structural determinants of interaction and assembly of the replication complex could provide a cornerstone for developing new antiviral strategies.

Our work within the VIZIER-Consortium has contributed to decipher the activity of the norovirus RdRp, showing that the active form of the viral RdRp of noroviruses is a homodimer displaying a positive cooperativity ([@bib86]). Our results also show that homodimerization of norovirus NS7 monomers is concentration-dependent, and that the apparent K~D~ of homodimerization lies within the nM range. Moreover, the monomers display a positive cooperativity *in vitro*. Similar observations on the NS6-7^propol^ of FCV cultivated in cell systems were reported ([@bib102]).

Here, the development of antiviral strategies aiming at destabilizing the interaction between the NS7^pol^ monomers is of interest. Another approach may rely on targeting the interaction of the structural proteins within the replication complex.

2.7. Targeting the post-replicative steps
-----------------------------------------

Following replication of the viral genome, further steps such as the assembly of the capsid protein, budding of the virions in the endoplasmic reticulum, transport and maturation of the virions in the ER and the Golgi complex, and vesicle fusion lead to release of the mature virions. Recent experimental data on the feline calicivirus has shown that upon infection, 3 viral non-structural proteins (p32, p30, and p39) co-localize to the ER, leading to a morphological changes of the ER membranes ([@bib8]). It remains however unclear whether these rearrangements are incriminated in the assembly of the replication complex, or not.

For other caliciviruses, these steps are poorly understood. Therefore, antiviral strategies targeting the post-replicative steps of the genome will not be developed, until substantial knowledge of those steps is generated.

3. Vaccines and other approaches
================================

Immunity to human pathogenic caliciviruses is very poorly understood, mainly because of a lack of cell culture systems to investigate neutralization of virus multiplication by serum or intestinal secretory antibodies. However, volunteer challenge studies have established that human pathogenic caliciviruses and particularly noroviruses induce two forms of immunity: a short-term and a long-term immunity ([@bib6], [@bib165], [@bib240]). Short-term immunity is virus-specific; individuals infected with a norovirus strain are resistant to re-infection with the same strain for up to 14 weeks following primary infection. Long-term immunity, in contrast, confers resistance to infection that lasts about 34 months following primary infection. Another interesting aspect relates to the type of cell-mediated immunity following infection with the human pathogenic calicivirus, i.e. norovirus. Volunteer challenge studies have shown that the cell-mediated immune response to norovirus infection displays a Th-1 dominant pattern ([@bib116]). In animal models, important insights into norovirus immunity to infection as well as pathogenesis have been generated recently based on the surrogate MNV ([@bib119], [@bib9], [@bib139], [@bib145]).

Virus-like particles that mimic structurally and antigenically the native capsid protein have been extensively used to explore the function and reactivity of noroviruses and sapoviruses ([@bib75], [@bib79], [@bib80], [@bib100], [@bib154]). VLPs are produced to relatively high yields in baculovirus recombinant expression systems or in the human endothelial kidney cell line HEK-293T ([@bib222]) assembling in the absence of the VP2, although the VP2 seems to enhance VLPs stability ([@bib68], [@bib99]). Furthermore, feeding of volunteers and laboratory animals with norovirus virus-like particles generated in tomato plants ([@bib93]) or potato plants ([@bib218]) led to an immune response (IgG and IgA) with variable intensity, depending on the adjuvant used. These and other previous data on vaccination ([@bib73], [@bib10]) to control infection by human caliciviruses is encouraging and deserves further development and evaluation.

For FCV, a vaccine is available ([@bib179]). The development of an efficient vaccine was possible because FCV can be amplified in CRFK cells, and a small model (felines) is also available. FCV vaccines use either attenuated or inactivated virus. Furthermore, dual-strain FCV vaccines consisting of virulent and attenuated strains have already been successfully implemented in clinical trials ([@bib88]). VLPs have also been effective in generating neutralizing antibodies in rabbits against various FCV strains, indicating that they could represent an interesting alternative to attenuated or inactivated viruses for production of FCV vaccines ([@bib40]).

In a recent study ([@bib121]), multivalent norovirus VLPs adjuvanted with alphavirus or CpG DNA were administrated to mice. The VLPs induced a mucosal and systemic immune response, and a reduction of viral titer in immunized mice following MNV challenge. Sera from immunized mice proved to be protective against MNV when transferred to immunodeficient mice. Similarly, VLPs representing RHDV and bearing a T cell epitope from ovalbumin were shown to be able to elicit a T cell immune response in dendritic cells, and to induce a cellular immune response in mice ([@bib37]).

These data are encouraging and highlight the potential of the VLP-based approach for the development of calicivirus vaccines.

Another experimental approach is based on inhibition of norovirus replication by interferon. Using a reverse genetics system for NV, [@bib25] have shown that IFN-α and IFN-γ inhibit translation and replication of calicivirus in a dose-dependent manner *in vitro*. As a correlate, the susceptibility of MNV to IFN was observed *in vitro* ([@bib29], [@bib238]) and also *in vivo* ([@bib105]). Although the observed EC~50~ was in the micromolar range, these data are of interest in the context of the antiviral effect of IFN on caliciviruses.

A more general approach for treatment of human pathogenic calicivirus infection has relied on the substitution of electrolytes and water loss by *per os* or *per enteral* rehydration, representing hence a symptomatic treatment of the infection ([@bib4]), but not an antiviral approach. The positive effect of nitazoxanide in controlling norovirus infections has also been described ([@bib186]).

4. Conclusions and future prospects
===================================

The possibility to cultivate members of three genera, noroviruses, vesiviruses, and recoviruses within the family *Caliciviridae*, is an important step towards better understanding of the replication cycle of these viruses and also the development of effective antiviral strategies. Nevertheless, there is clearly a need for culture systems to propagate the human pathogenic variants of noroviruses and sapoviruses in mammalian cells. This has hampered the development of antiviral approaches as well as vaccines, but also the in-depth study of the pathogenicity of the human pathogenic calicivirus, accounting for the slow progress in the field.

One of the potential problems caused by the treatment of calicivirus infections will be, as observed for other RNA viruses with a positive stranded genome, the emergence of drug resistance. The major problem lies in the high genomic variability of the strains in particular for human pathogenic noroviruses, as well as the accelerating emergence of new variants. Therefore, antiviral strategies should aim at targeting conserved regions in the viral genome and possibly not exposed to immunological pressure leading to immune escape. Because of the short duration of the disease, treatment of calicivirus infection may focus on the containment of the infection in the context of outbreaks, as well as long-term shedding of the virions after infection, as observed following infection with noroviruses.
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